2.2. Subjects
mood disorders
RECRUITMENT
All subjects gave their informed consent for inclusion before they participated. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the University of Northern Colorado Institutional Review Board (IRB). All participants met the following inclusion criteria: 18–50 years old, 6 weeks of abstinence from cannabis (either tetrahydrocannabinol (THC) and/or CBD), and no chronic alcohol and/or drug use. Participants were excluded if they were diagnosed with cardiovascular, neurological, metabolic, or mood disorders, were pregnant and/or nursing, or were unable to adhere to an 8-week supplement intervention. All participants were informed of the benefits and risks of the investigation prior to signing the IRB-approved consent form. Participants were randomly assigned following simple randomization procedures to 1 of 2 treatments: CBD intervention group (CG) or placebo group (PG). Randomization and supplement allocation was conducted by an independent investigator with no involvement in the recruitment, consent, or data collection and analysis processes.